Full text
Earnings transcript
Read the complete earnings call transcript.
GEHC
GE HealthCare Technologies Inc.
$65.76
-0.25
(-0.38%)
| Exchange: | NASDAQ |
| Market Cap: | 29.914B |
| Shares Outstanding: | 454.71M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Healthcare Information Services | |||||
| CEO: | Peter J. Arduini | |||||
| Full Time Employees: | 53000 | |||||
| Address: |
| |||||
| Website: | https://www.gehealthcare.com |
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women’s health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women’s health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 19,552,000 | 19,672,000 | 20,625,000 |
| Gross Profit | 7,922,000 | 8,205,000 | 8,247,000 |
| EBITDA | 3,513,000 | 3,666,000 | 3,785,000 |
| Operating Income | 2,435,000 | 2,625,000 | 2,762,000 |
| Net Income | 1,568,000 | 1,993,000 | 2,084,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 32,454,000 | 33,089,000 | 36,906,000 |
| Total Liabilities | 25,144,000 | 24,437,000 | 26,307,000 |
| Total Stockholders Equity | 7,133,000 | 8,446,000 | 10,379,000 |
| Total Debt | 9,863,000 | 9,376,000 | 508,000 |
| Cash and Cash Equivalents | 2,494,000 | 2,874,000 | 4,512,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 2,101,000 | 1,951,000 | 0 |
| Capital Expenditure | -387,000 | -401,000 | -482,000 |
| Free Cash Flow | 1,714,000 | 1,550,000 | -482,000 |
| Net Income | 1,568,000 | 2,050,000 | 2,154,000 |
| Net Change in Cash | 1,055,000 | 387,000 | 1,622,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2029 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 25,359,736.543 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 25,914,068.245 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 25,688,609.286 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 4,683,528.661 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 4,785,904.662 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 4,744,266.079 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 3,086,532.831 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 3,174,583.242 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 3,138,769.324 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 5,282,183.495 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 5,397,645.332 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 5,350,684.450 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 6.820 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 6.900 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 6.710 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 9 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 3 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Revenue Performance: GEHC has demonstrated consistent revenue growth as reported in recent income statements, with strong gross profit margins (per grossProfitMarginTTM) reflecting operational efficiency. This aligns with positive industry trends in the healthcare equipment and services sector (industryName, sectorName), indicating a competitive position.
- Solid Cash Flow Generation: High free cash flow (freeCashFlowYieldTTM and freeCashFlow from cash flow statements) underscores GEHC’s ability to fund innovation and capital expenditures (investmentsInPropertyPlantAndEquipment), supporting long-term growth initiatives without over-reliance on external financing.
- Strong Market Position: As a key player in the healthcare sector (description, sectorName), GEHC benefits from a large market cap (mktCap) and a global presence (revenue from Revenue Geo Segments), providing stability and diversified revenue streams across regions.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates GEHC intrinsic value between $49.69 – $90.40 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about GEHC valuation
Is GE HealthCare Technologies Inc. (GEHC) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for GE HealthCare Technologies Inc. (GEHC) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is GEHC a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether GEHC trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is GEHC’s P/E ratio?
You can see GEHC’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for GEHC?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is GEHC a good long-term investment?
Whether GEHC fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
GEHC
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-0.38
Trading Metrics:
| Open: | 65.69 | Previous Close: | 66.01 | |
| Day Low: | 65.07 | Day High: | 66.25 | |
| Year Low: | 58.75 | Year High: | 89.77 | |
| Price Avg 50: | 66.5 | Price Avg 200: | 75.04 | |
| Volume: | 732879 | Average Volume: | 4.842M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeGEHC full analysis
Welcome to MARKETSNAP’s SWOT analysis for GE HealthCare Technologies, or GEHC as it’s known on the ticker. If you’re a long-term investor looking to build wealth, you’re in the right place. Today, we’re diving deep into what makes GE HealthCare tick, breaking down its strengths, weaknesses, opportunities, and threats. I’ll keep this conversational and packed with insights, so let’s get started with a quick overview of who they are and what’s been happening with this company lately. GE HealthCare Technologies…
